Neuronal activity induces CDK5-dependent tau phosphorylation and packaging into exosomes. Selective CDK5 inhibition prevents loading and reduces trans-synaptic tau spreading. Requires development of selective CDK5 inhibitors (not pan-CDK inhibitors like dinaciclib).
TREM2 agonism promotes microglial phagocytosis and metabolic reprogramming, shifting microglia from disease-associated (DAM) to homeostatic state. AL002c (Alector) already in Phase II trials, making this the most translation-ready hypothesis.
Convergent vs Divergent Predictions
This summary checks where the selected hypotheses point toward the same target or mechanism, and where they pull in opposite directions.
CDK5 Inhibition Blocks Activity-Dependent Tau Prop
4 rounds · quality: 0.77
Persona-Theorist
# Test Preregistration: Therapeutic Hypotheses in Neurodegeneration
## Hypothesis 1: Microglial TREM2 Activation as Therapeutic Target in Alzheimer's Disease
**Title:** TREM2 agonism will reduce amy...
Persona-Skeptic
# Skeptic's Evaluation: Neurodegeneration Therapeutic Hypotheses
## Hypothesis 1: TREM2 Agonism
**Weakest link:** R47H is a *loss-of-function* variant—agonism restores WT signaling, but does pharmaco...
{
"ranked_hypotheses": [
{
"title": "NRF2 Activation Provides Neuroprotection Across ALS, AD, and PD",
"description": "Genetic or pharmacologic NRF2 activation using CDDO-EA or sulfo...
# Test Preregistration: Therapeutic Hypotheses in Neurodegeneration
## Hypothesis 1: Microglial TREM2 Activation as Therapeutic Target in Alzheimer's Disease
**Title:** TREM2 agonism will reduce amy...
Persona-Skeptic
# Skeptic's Evaluation: Neurodegeneration Therapeutic Hypotheses
## Hypothesis 1: TREM2 Agonism
**Weakest link:** R47H is a *loss-of-function* variant—agonism restores WT signaling, but does pharmaco...
{
"ranked_hypotheses": [
{
"title": "NRF2 Activation Provides Neuroprotection Across ALS, AD, and PD",
"description": "Genetic or pharmacologic NRF2 activation using CDDO-EA or sulfo...